Categories: AnalystsCannabis

Aurora Cannabis will be a top five producer, GMP says

Following an equity financing that shored up he company’s balance sheet, GMP Securities analyst Martin Landry has resumed coverage of Aurora Cannabis (TSX:ACB) with a price target hike.

In a research update to clients today, Landry maintained his “Buy” rating, but raised his one-year price target on Aurora from $3.25 to $3.75, implying a return of 23 per cent at the time of publication.

This morning, Aurora Cannabis announced it had completed a $69-million bought deal financing. The company said it planned to use the proceeds for a domestic and international expansion. Landry says this development means the company can look squarely forward.

“With Aurora Sky now fully funded (100,000kg), and well positioned both domestically and internationally, Aurora is poised to capitalize on the growth of the global cannabis sector,” the analyst says. “We raise our target price to reflect our new recreational market assumptions. Our target is derived from a DCF analysis using: (1) a 10% discount rate (unchanged), (2) average market share of ~9% and an average EBITDA margin of ~28% (unchanged), and (3) a terminal growth rate of 3%.”

Landry thinks Aurora Cannabis will generate EBITDA of $6.3-million on revenue of $68.0-million in fiscal 2018. He expects those numbers will improve to EBITDA of $87.2-million on a topline of $230.5-million the following year.

The analyst says the company’s capacity expansion comes at the right time to capture market share.

“With the first harvest at Aurora Sky expected in April 2018, this should translate into an annual runrate production capacity of ~10,000–12,000kg leading into the opening of the recreational market,” Landry says. “We believe this places ACB among the top five largest producers in the industry at the outset of recreational; not only providing Aurora with solid positioning to capture market share, but also making ACB a strong candidate to sign supply agreements with provincial governments.”

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

9 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

15 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

16 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

17 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago